The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion

Leukemia

Volumn 21, Issue 5, 2007, Pages 886-896

  Tazzari, P L ^a   Tabellini, G ^b   Bortul, R ^c   Papa, V ^d   Evangelisti, C ^d   Grafone, T ^d   Martinelli, G ^d   McCubrey, J A ^e   Martelli, A M ^d,f  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e EAST CAROLINA UNIVERSITY   (United States)

^f CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CASPASE 3; CD34 ANTIGEN; CELL CYCLE PROTEIN; CYTARABINE; ETOPOSIDE; FLICE INHIBITORY PROTEIN; FLUDARABINE; IDARUBICIN; MITOXANTRONE; NVP AEW 541; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN HL 60; CELL SURVIVAL; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME DEGRADATION; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

EID: 34247636761     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404643     Document Type: Article

References (50)

1. Valentinis B, Baserga R. IGF-1 receptor signalling in transformation and differentiation. Mol Pathol 2001; 54: 133-137.
2. Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 2005; 65: 10123-10127.
3. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006; 94: 465-468.
4. Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 2006; 1766: 1-22.
5. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489.
6. LeRoith D, Roberts Jr CT. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-137.
7. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107: 873-877.
8. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 2856-2861.
9. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104: 607-618.
10. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230.
11. Freund GG, Kulas DT, Way BA, Mooney RA. Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lympho-blastoid cell lines. Cancer Res 1994; 54: 3179-3185.
12. Grandage VL, Gale RE, Linch DC, Khwaja A. P13-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-κB, Mapkinase and p53 pathways. Leukemia 2005; 19: 586-594.
13. Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 2005; 19: 1543-1549.
14. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, P13K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189-218.
15. Kubota Y, Tanaka T, Ohnishi H, Kitanaka A, Okutani Y, Taminato T et al. Constitutive activation of P13K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: Direct evidence of P13K activation. Leukemia 2004; 18: 1438-1440.
16. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T et al. Multidrug resistence-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007, in press.
17. Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G et al. The phosphoinositide 3-kinase/Akt 1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 2003; 1: 234-246.
18. Cappellini A, Tabellini G, Zweyer M, Bortul R, Tazzari PL, Billi AM et al. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip 1) and control of cyclin D, expression. Leukemia 2003; 17: 2157-2167.
19. Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003; 17: 1794-1805.
20. Bortul R, Tazzari PL, Cappellini A, Tabellini G, Billi AM, Bareggi R et al. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) upregulation. Leukemia 2003; 17: 379-389.
21. Casas S, Ollila J, Aventin A, Vihinen M, Sierra J, Knuutila S. Changes in apoptosis-related pathways in acute myelocytic leukemia. Cancer Genet Cytogenet 2003; 146: 89-101.
22. Estrov Z, Meir R, Barak Y, Zaizov R, Zadik Z. Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol 1991; 9: 394-399.
23. Surmacz E. Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor. Oncogene 2003; 22: 6589-6597.
24. Burtrum DA, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63: 8912-8921.
25. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005; 11: 3065-3074.
26. Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and P13K/ Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 2006; 20: 254-1260.
27. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C et al. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 5: 2503-2512.
28. Blum G, Gazit A, Levitzki A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 2000; 39: 15705-15712.
29. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231-239.
30. Bjorndahl M, Cao R, Nissen LJ, Clasper S, Johnson LA, Xue Y et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 15593-15598.
31. Neuvians TP, Gashaw I, Hasenfus A, Hacherhacker A, Winterhager E, Grobholz R. Differential expression of IGF components and insulin receptor isoforms in human seminoma versus normal testicular tissue. Neoplasia 2005; 7: 446-456.
32. Tabellini G, Cappellini A, Tazzari PL, Fala F, Billi AM, Manzoli L et al. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 2005; 202 623-634.
33. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65: 3868-3876.
34. Hopfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherubl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 2006; 71: 1435-1448.
35. Coutant A, Rescan C, Gilot D, Loyer P, Guguen-Guillouzo C, Baffet G. P13K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival. Hepatology 2002; 36: 1079-1088.
36. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004; 10: 1013-1023.
37. 1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-3511.
38. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3β: Key regulators of progression to androgen-independent prostate cancer. Oncogene 2006; 25: 329-337.
39. Assoian RK. Stopping and going with p27kip1. Dev Cell 2004; 6 458-459.
40. Yang H, Zhang Y, Zhao R, Wen YY, Fournier K, Wu HB et al. Negative cell cycle regulator 14-3-3σ stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt. Oncogene 2006; 25: 4585-4594.
41. Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 2006; 100: 389-396.
42. Hail Jr N, Carter BZ, Konopleva M, Andreeff M. Apoptosis effector mechanisms: A requiem performed in different keys. Apoptosis 2006; 11: 889-904.
43. Samani AA, Yakar 5, Leroith D, Brodt P. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 2007, in press.
44. Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: There is more to life than Bcl2. Oncogene 2003; 22: 8568-8580.
45. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-1. Cytokine Growth Factor Rev 2006; 17: 305-323.
46. Martelli AM, Nyakem M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006; 20: 911-928.
47. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/P13-K/PKB-dependent pathway. Leukemia 2004; 18: 103-112.
48. Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2006; 20: 952-957.
49. Karajannis MA, Vincent L, Direnzo R, Shmelkov SV, Zhang F, Feldman EJ. Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia 2006; 20: 979-986.
50. Abe S, Funato T, Takahashi S, Yokoyama H, Yamamoto J, Tomiya Y et al. Increased expression of insulin-like growth factor I is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 2006; 209 217-228.